BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) is a clinical-stage oncology company that entered the public markets through a SPAC transaction and operates in the biopharmaceutical sector with a focus on cancer therapeutics. The company filed a 424B3 prospectus with the SEC on May 6, 2026, under accession number 0001193125-26-208937, a form type commonly associated with resale registrations and ongoing shareholder disclosures in the post-merger phase of a SPAC lifecycle. BBOT reflects the broader trend of oncology-focused biotechs accessing public capital markets via the SPAC route. For full filing history, sponsor details, and deal analytics on BBOT, sign up for complete data access at SpacDesk.